These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 33686517)

  • 21. Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models.
    Issa A; Gill JW; Heideman MR; Sahin O; Wiemann S; Dey JH; Hynes NE
    Breast Cancer Res; 2013 Jan; 15(1):R8. PubMed ID: 23343422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the PI3K Pathway in Head and Neck Squamous Cell Carcinoma.
    Isaacsson Velho PH; Castro G; Chung CH
    Am Soc Clin Oncol Educ Book; 2015; ():123-8. PubMed ID: 25993150
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
    Beck JT; Ismail A; Tolomeo C
    Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
    Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
    Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations.
    Wang Z; Martin D; Molinolo AA; Patel V; Iglesias-Bartolome R; Degese MS; Vitale-Cross L; Chen Q; Gutkind JS
    J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25099740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cetyltrimethylammonium Bromide Attenuates the Mesenchymal Characteristics of Hypopharyngeal Squamous Cell Carcinoma Through Inhibiting the EGFR/PI3K/AKT Signaling Pathway.
    Wu TK; Ou YC; Chen YP; Huang FM; Pan YR; Lee CJ
    Anticancer Res; 2021 Aug; 41(8):3789-3799. PubMed ID: 34281838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel EGFR ectodomain mutations associated with ligand-independent activation and cetuximab resistance in head and neck cancer.
    Nair S; Trummell HQ; Rajbhandari R; Thudi NK; Nozell SE; Warram JM; Willey CD; Yang ES; Placzek WJ; Bonner JA; Bredel M
    PLoS One; 2020; 15(2):e0229077. PubMed ID: 32069320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. p-mTOR, p-ERK and PTEN Expression in Tumor Biopsies and Organoids as Predictive Biomarkers for Patients with HPV Negative Head and Neck Cancer.
    de Kort WWB; de Ruiter EJ; Haakma WE; Driehuis E; Devriese LA; van Es RJJ; Willems SM
    Head Neck Pathol; 2023 Sep; 17(3):697-707. PubMed ID: 37486536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3Kα inhibition in controlling tumor growth.
    Ruicci KM; Meens J; Sun RX; Rizzo G; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Boutros PC; Ailles L; Nichols AC
    Int J Cancer; 2019 Oct; 145(8):2100-2106. PubMed ID: 30468243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
    Gadgeel SM; Wozniak A
    Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
    Le Tourneau C; Siu LL
    Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EGFR/PI3K/Akt/mTOR pathway in head and neck squamous cell carcinoma patients with different HPV status.
    Janecka-Widła A; Majchrzyk K; Mucha-Małecka A; Biesaga B
    Pol J Pathol; 2021; 72(4):296-314. PubMed ID: 35142162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HOXB5 acts as an oncogenic driver in head and neck squamous cell carcinoma via EGFR/Akt/Wnt/β-catenin signaling axis.
    Lee K; Chang JW; Oh C; Liu L; Jung SN; Won HR; Kim YI; Rha KS; Koo BS
    Eur J Surg Oncol; 2020 Jun; 46(6):1066-1073. PubMed ID: 31864826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting mTOR-CCL20 Signaling May Improve Response to Docetaxel in Head and Neck Squamous Cell Carcinoma.
    Chou MH; Chuang HC; Lin YT; Tsai MH; Kao YH; Lin IC; Huang TL; Fang FM; Chien CY
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.
    Michmerhuizen NL; Leonard E; Matovina C; Harris M; Herbst G; Kulkarni A; Zhai J; Jiang H; Carey TE; Brenner JC
    Mol Pharmacol; 2019 May; 95(5):528-536. PubMed ID: 30858165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
    Singh SS; Yap WN; Arfuso F; Kar S; Wang C; Cai W; Dharmarajan AM; Sethi G; Kumar AP
    World J Gastroenterol; 2015 Nov; 21(43):12261-73. PubMed ID: 26604635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.
    Ather F; Hamidi H; Fejzo MS; Letrent S; Finn RS; Kabbinavar F; Head C; Wong SG
    PLoS One; 2013; 8(2):e56112. PubMed ID: 23405260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DKK3 knockdown confers negative effects on the malignant potency of head and neck squamous cell carcinoma cells via the PI3K/Akt and MAPK signaling pathways.
    Katase N; Nishimatsu SI; Yamauchi A; Yamamura M; Fujita S
    Int J Oncol; 2019 Mar; 54(3):1021-1032. PubMed ID: 30569110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular pathways in head and neck cancer: EGFR, PI3K, and more.
    Psyrri A; Seiwert TY; Jimeno A
    Am Soc Clin Oncol Educ Book; 2013; ():246-55. PubMed ID: 23714515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of GRB2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma.
    Hoeben A; Martin D; Clement PM; Cools J; Gutkind JS
    Int J Cancer; 2013 Mar; 132(5):1042-50. PubMed ID: 22865653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.